Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine of meetings, deadlines, and conference calls has returned, despite the short week on this side of the pond. To cope, we are doing the usual — brewing cups of stimulation (pumpkin spice, so far today) and we invite you to join us. Remember, no prescription is required, so no need to check on copays. Meanwhile, here are some tidbits. Have a glorious day and keep in touch. …

The American Pain Society voted to cease operations and filed for Chapter 7 bankruptcy protection, which refers to liquidation. The move comes after the organization blamed financial problems that have been exacerbated by the mounting expenses associated with defending lawsuits filed by local, city, and state governments over the opioid crisis. Along with drug makers and wholesalers, the professional society was named as a defendant in many of the cases.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy